MedX Announces Final Closing of Non-Brokered Private Placement
MISSISSAUGA, Ontario, June 09, 2025--(BUSINESS WIRE)--MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) is pleased to announce that, further to its Press Releases dated April 7, and May 22, 2025, announcing an Initial Closing and further Closing, it has completed a final Closing of the Non-brokered Private Placement to accredited investors originally announced in its Press Release dated February 25, 2025. The Final Closing comprised the issuance of 8,678,571 Units (as described below) and raised cash proceeds of $607,500, bringing the total amount raised in the Placement to $2,063,500. Securities issued are subject to a regulatory "hold" period of four months and one day from the date of issuance. Under this Non-Brokered Private Placement, the Company issued a total of 29,478,571 Units at $0.07 per Unit ("Unit"). Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant ("Warrant(s)"), exercisable to purchase One (1) further Common Share at the price of $0.09, during the period of one year commencing on the date of issuance. Three Insiders participated in this Placement to the extent of $500,000, for the acquisition of a total of 7,142,857 Units. In connection with the issuance of Units to those Insiders, the Company relies on exemptions from formal valuation and minority shareholder approval requirements set out in Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101"). as (i) the fair market value of the proposed placement to the Insiders does not exceed 25% of the market capitalization of the Company and (ii) the conditions in section 5.7(1)(a), section 5.7(1)(b) and section 5.7(1)(e) of MI 61-101 are met.
Qualified agents received total cash commissions of $15,880, (equal to 8% of the gross proceeds received by the Company from the sale of the Units to subscribers introduced by such agent(s)), and 226,857 agent's warrants ("Agent's Warrant(s)") (equal to 8% of subscriptions introduced by such agent(s)). Each Agent's Warrant, which is non-transferable, entitles the holder to acquire, at the price of CAD$0.07, a unit, comprised of One (1) fully paid Common Share and one (1) non-transferable share purchase warrant ("Agent's Share Purchase Warrant"), entitling the holder to acquire one additional Common Share at the price of CAD$0.09. The Agent's Warrants and any Agent's Share Purchase Warrants that may be issued pursuant to exercise of an Agent's Warrant, if not exercised, will expire one year following the date of issuance.
Funds raised in this Placement are being be directed towards continuing development of the Company's leading edge SIAscopy® on DermSecure® telemedicine platform, building out the launch of its technology into the occupational health marketplace, and general corporate purposes.
About MedX Health Corp.:
MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union and Turkey. Visit https://medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250609640146/en/
Contacts
MedX Health Corp.Mike Druhan, President, Dermatological Servicesmike.druhan@medxhealth.com (+1) 905-599-7852
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Expansion of Tolmer 'Silver Zone' Drilling Program
Early surface reconnaissance and drilling progress sharpen silver focus HIGHLIGHTS Current ~2,500m reverse circulation (RC) drilling program underway at Tolmer discovery; planned gold drilling reallocated to prioritise silver zone following early observations1 Additional target holes added north, east, south and west of high-grade 'discovery line'2 ADELAIDE, AUSTRALIA / / June 9, 2025 / Barton Gold Holdings Limited (ASX:BGD)(FRA:BGD3)(OTCQB:BGDFF) (Barton or Company) is pleased to provide an update for RC drilling underway at its recent 'Tolmer' high grade silver discovery, located at the Company's South Australian Tarcoola Gold Project (Tarcoola).1 Drilling recently started at Tolmer with a priority focus on the western 'silver zone'.1 Planned gold drilling will now be deferred in favour of extending drilling at the silver zone, ahead of anticipated follow-up programs starting as early as late July. Figure 1 - Tolmer 'western silver' & 'eastern gold' zones showing expanded silver drilling lines Commenting on the revised drilling program, Barton Managing Director Alexander Scanlon said: "Based upon early observations we are refocusing all current Tolmer drilling on the western 'silver zone'. We will expedite these assays to inform near-term follow-up programs, likely to include orientation diamond drilling." Growing 'silver zone' footprint Barton identified Tolmer as a high-grade gold discovery in August 2024, and subsequently identified a new 'silver zone' ~500m west in a line of seven discovery holes with globally significant assays including:3 Hole ID Interval Including: TBAC130 6m @ 4,747 g/t Ag from 46 metres 1m @ 17,600 g/t Ag from 46 metres TBM227 4m @ 1,417 g/t Ag from 9 metres 1m @ 3,790 g/t Ag from 9 metres TBM228 14m @ 434 g/t Ag from 46 metres 1m @ 3,350 g/t Ag from 54 metres On 22 May Barton commenced a planned program of ~2,500m RC drilling which was designed to infill and extend both the western 'silver zone' and the eastern 'gold zone'.4 Based upon further geological surface reconnaissance and early observations from drilling, it was decided to expand the 'silver zone' drilling program to gather a larger amount of data on this area with the remaining time available in this program. Seven drill holes originally planned for the eastern 'gold zone' have been re-allocated to eight new drill holes in the western 'silver zone', expanding the planned drilling from three to five lines of RC holes. The total Tolmer drilling program has been expanded from a planned ~2,500m to a revised total of ~2,850m. Drilling of the expanded 'silver program' is now anticipated to finish this week, following which assays will be expedited for laboratory analysis and planning of follow up drilling programs. These will likely include additional RC drilling (including in the gold zone) and diamond drilling for structural orientation. Figure 2 - Tolmer 'silver zone' cross-section (see Fig. 2) with anomalous Ag-Pb and key intersections4 1 Refer to ASX announcement dated 22 May 2025 2 Refer to ASX announcements dated 27 August 2024 and 30 January, 27 March, 16 April and 12 / 22 May 2025 3 Refer to ASX announcements dated 27 August 2024 and 30 January, 6 February, 27 March, 16 April and 22 May 2025 4 Refer to ASX announcement dated 22 May 2025 Authorised by the Managing Director of Barton Gold Holdings Limited. For further information, please contact: Alexander ScanlonManaging 425 226 649 Jade CookCompany Secretarycosec@ 8 9322 1587 About Barton Gold Barton Gold is an ASX, OTCQB and Frankfurt Stock Exchange listed Australian gold developer targeting future gold production of 150,000ozpa with 1.7Moz Au & 3.1Moz Ag JORC Mineral Resources (64.0Mt @ 0.83 g/t Au), brownfield mines, and 100% ownership of the region's only gold mill in the renowned Gawler Craton of South Australia. Tarcoola Gold Project Fully permitted open pit mine with ~20koz Au within trucking distance of Barton's Central Gawler Mill Historical goldfield with new high-grade gold-silver discovery in grades up to 83.6 g/t Au and 17,600 g/t Ag Tunkillia Gold Project 1.6Moz Au & 3.1Moz Ag JORC Mineral Resources Optimised Scoping Study for competitive ~120kozpa gold and ~250kozpa silver bulk open pit operation Key Regional Infrastructure Region's only gold processing plant (650ktpa CIP) Multiple camps / accommodation across projects Competent Persons Statement & Previously Reported Information The information in this announcement that relates to the historic Exploration Results and Mineral Resources as listed in the table below is based on, and fairly represents, information and supporting documentation prepared by the Competent Person whose name appears in the same row, who is an employee of or independent consultant to the Company and is a Member or Fellow of the Australasian Institute of Mining and Metallurgy (AusIMM), Australian Institute of Geoscientists (AIG) or a Recognised Professional Organisation (RPO). Each person named in the table below has sufficient experience which is relevant to the style of mineralisation and types of deposits under consideration and to the activity which he has undertaken to quality as a Competent Person as defined in the JORC Code 2012 (JORC). Activity Competent Person Membership Status Tarcoola Mineral Resource (Stockpiles) Dr Andrew Fowler (Consultant) AusIMM Member Tarcoola Mineral Resource (Perseverance Mine) Mr Ian Taylor (Consultant) AusIMM Fellow Tarcoola Exploration Results (until 15 Nov 2021) Mr Colin Skidmore (Consultant) AIG Member Tarcoola Exploration Results (after 15 Nov 2021) Mr Marc Twining (Employee) AusIMM Member Tunkillia Exploration Results (until 15 Nov 2021) Mr Colin Skidmore (Consultant) AIG Member Tunkillia Exploration Results (after 15 Nov 2021) Mr Marc Twining (Employee) AusIMM Member Tunkillia Mineral Resource Mr Ian Taylor (Consultant) AusIMM Fellow Challenger Mineral Resource Mr Dale Sims (Consultant) AusIMM / AIG Fellow / Member The information relating to historic Exploration Results and Mineral Resources in this announcement is extracted from the Company's Prospectus dated 14 May 2021 or as otherwise noted in this announcement, available from the Company's website at or on the ASX website The Company confirms that it is not aware of any new information or data that materially affects the Exploration Results and Mineral Resource information included in previous announcements and, in the case of estimates of Mineral Resources, that all material assumptions and technical parameters underpinning the estimates, and any production targets and forecast financial information derived from the production targets, continue to apply and have not materially changed. The Company confirms that the form and context in which the applicable Competent Persons' findings are presented have not been materially modified from the previous announcements. Cautionary Statement Regarding Forward-Looking Information This document may contain forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "expect", "target" and "intend" and statements than an event or result "may", "will", "should", "would", "could", or "might" occur or be achieved and other similar expressions. Forward-looking information is subject to business, legal and economic risks and uncertainties and other factors that could cause actual results to differ materially from those contained in forward-looking statements. Such factors include, among other things, risks relating to property interests, the global economic climate, commodity prices, sovereign and legal risks, and environmental risks. Forward-looking statements are based upon estimates and opinions at the date the statements are made. Barton undertakes no obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates or to update or keep current any of the information contained herein. Any estimates or projections as to events that may occur in the future (including projections of revenue, expense, net income and performance) are based upon the best judgment of Barton from information available as of the date of this document. There is no guarantee that any of these estimates or projections will be achieved. Actual results will vary from the projections and such variations may be material. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. Any reliance placed by the reader on this document, or on any forward-looking statement contained in or referred to in this document will be solely at the readers own risk, and readers are cautioned not to place undue reliance on forward-looking statements due to the inherent uncertainty thereof. * Refer to Barton Prospectus dated 14 May 2021 and ASX announcement dated 4 March 2025. Total Barton JORC (2012) Mineral Resources include 909koz Au (30.8Mt @ 0.92 g/t Au) in Indicated category and 799koz Au (33.2Mt @ 0.75 g/t Au) in Inferred category, and 3,070koz Ag (34.5Mt @ 2.80 g/t Ag) in Inferred category as a subset of Tunkillia gold JORC (2012) Mineral Resources. SOURCE: Barton Gold Holdings Limited View the original press release on ACCESS Newswire
Business Insider
an hour ago
- Business Insider
AT&T reiterates FY25 financial and operational guidance
The company stated: 'AT& T continues to execute on its multi-year growth plan and differentiate its position within the connectivity industry by increasing its opportunity to serve customers how they want to be served, by one provider with fiber and 5G in a converged manner. The Company recently announced an agreement to acquire substantially all of Lumen's Mass Markets fiber internet connectivity business. The transaction, which is expected to close in the first half of 2026, will expand investment in critical U.S. connectivity infrastructure, create new middle-class jobs and accelerate high-speed fiber internet access to millions of Americans. Additionally, this deal will enable AT&T to significantly expand access to AT&T Fiber in new major metro areas and allow the Company to serve more customers with 5G and fiber together. AT&T continues to extend its fiber leadership with plans to reach approximately 60 million total fiber locations by year-end 2030. Ultimately, this transaction aligns with the priorities outlined at AT&T's 2024 Analyst & Investor Day, including its goal of becoming the best connectivity provider in America while providing more value to customers, shareholders and the Company. AT&T is seeing solid customer demand and remains on track to achieve its 2025 financial and operational guidance. The wireless industry remains both healthy and competitive, and the Company is pleased with how the Mobility business is performing in the second quarter. In Consumer Wireline, the Company continues to expand access to AT&T Fiber – America's fastest internet with the most reliable speeds.2 Trends in AT&T Fiber penetration rates remain consistent, with net adds varying from quarter to quarter based primarily on the pace of new fiber locations passed, seasonality and marketplace dynamics. For the second-quarter 2025, the Company continues to expect capital investment in the $4.5 billion to $5 billion range and free cash flow of approximately $4 billion. AT&T reiterates all full-year 2025 financial and operational guidance. Additionally, the Company continues to operate the business to achieve the financial plan and capital returns outlined at its 2024 Analyst & Investor Day. AT&T remains committed to repurchasing shares under the previously announced $10 billion authorization, with plans to repurchase at least $3 billion of common stock by year-end and the remainder during 2026.' Confident Investing Starts Here:
Yahoo
an hour ago
- Yahoo
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership Capacities MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. 'On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company' commented John Seaberg, Chairman of Anteris. 'On the heels of our Q4 2024 listing onto NASDAQ, and as we ramp-up activities to launch the DurAVR® THV global, pivotal clinical trial (the "PARADIGM Trial"), we are excited to enhance the leadership team with two highly accomplished, U.S. based, healthcare executives as the company transitions to its next phase of growth. I also wish to extend gratitude to Dr. Gu for his commitment and contributions to the company over the course of his tenure as a member of the Board and wish him well on his future endeavors.' Mr. David Roberts is currently President of LeMaitre Vascular, Inc. (NASDAQ: LMAT), a position he has held since 2007. He joined LeMaitre in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000. Prior to LeMaitre, Mr. Roberts served as Vice President of Development for BUCA, Inc. from 1994 to 1997, and prior to that as Associate of HarbourVest Partners from 1992 to 1994. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts serves as a director of LeMaitre Vascular, Inc., Lexington Medical, Inc. and Parasole Restaurant Holdings, Inc. Mr. Gregory Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune, Inc. Prior to Evommune, Mr. Moss served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon's $1.9 billion acquisition in 2021. Prior to joining Kadmon in 2012, Mr. Moss served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes. Mr. Moss currently serves on the board of Vitls, Inc. Mr. Moss earned a BA and an LLB from Macquarie University, Australia, and is a member of the Bar Associations of New York, USA, and New South Wales, Australia, with admissions before the Supreme Court of the United States of America; Southern District of New York; Supreme Court of New South Wales, Australia; and High Court of Australia. Mr. Roberts and Mr. Moss will help guide Anteris through its next phase of growth, with the upcoming global pivotal PARADIGM study in 3Q2025 towards the ultimate U.S. and EMA licensure of the DurAVR® THV for patients with aortic stenosis. About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris' lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. For more information: Investor Relations investor@ OrmsbyAnteris Technologies Global Corp.+61 1300 550 310 | +61 7 3152 3200 Investor Relations (US)mchatterjee@ Chatterjee, Life Science Group+1 917 330 4269WebsiteXFacebookLinkedIn in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
